Evidence map›Paper›PMID 30346951›Full record

ArticlePloS one2018

Pancreatic autoimmunity: An unknown etiology on patients with assisted reproductive techniques (ART)-recurrent reproductive failure.

Diana Alecsandru, Ana Barrio, Victor Andia, Edgar Cruz, Pilar Aparicio, Jose Serna, Maria Cruz, Antonio Pellicer, Juan Antonio Garcia-Velasco

Full text read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Diana AlecsandruDepartment of Immunology and Department of Reproductive Endocrinology and Infertility, Valentian Infertility Institute (IVI), IVI RMA, Madrid, Madrid, Spain.
Ana BarrioDepartment of Immunology and Department of Reproductive Endocrinology and Infertility, Valentian Infertility Institute (IVI), IVI RMA, Madrid, Madrid, Spain.
Victor AndiaDepartment of Endocrinology and Diabetes, Gregorio Marañon University Hospital, Madrid.
Edgar CruzValencian Infertility Institute (IVI), IVI RMA, Madrid, Spain.ORCID 0000-0002-7579-7814
Pilar AparicioDepartment of Immunology and Department of Reproductive Endocrinology and Infertility, Valentian Infertility Institute (IVI), IVI RMA, Madrid, Madrid, Spain.
Jose SernaValencian Infertility Institute (IVI), IVI RMA, Zaragoza, Spain.
Maria CruzValencian Infertility Institute (IVI), IVI RMA, Madrid, Spain.
Antonio PellicerValencian Infertility Institute (IVI), IVI RMA, Valencia, Spain.
Juan Antonio Garcia-VelascoDepartment of Immunology and Department of Reproductive Endocrinology and Infertility, Valentian Infertility Institute (IVI), IVI RMA, Madrid, Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic Autoimmunity is defined as the presence of autoantibodies and more frequent need for insulin treatment. Affected women presenting recurrent implantation failure (RIF) or recurrent miscarriage (RM) are often misdiagnosed. The objective of thestudy was to describe clinical and metabolic profiles suggestive of Pancreatic Autoimmunity and therapeutic strategy in patients with RIF/RM. We analyzed retrospectively 735 patients, and have identified a subset (N = 20) with similar metabolic characteristics. At the same time, we included a control group (n = 39), with similar demographic characteristics and negative for pancreatic, thyroid or celiac disease autoimmunity. The patients identified with autoimmune metabolic problem (N = 20) had relatives with diabetes mellitus. At 120 minutes after Oral Glucose Tolerance Test (OGTT) low level of insulin secretion (<2 IU/ml) was found in 70% of patients. Glutamic acid decarboxylase 65 (GAD 65) antibodies, with or without other autoantibodies, were positive in80% of patients and anti-IA2 alone were positive I the rest. Since pregestational period, insulin administration was recommended for 10 patients, metformin for 4 patients and exclusively diet control in 5 of them. Significantly increased live bith rates (LBR) per cycle were observed after metabolic control (52%) compared with live birth rate (LBR) after cycles without control (7.5%) (p<0.0001). We noticed 2 cases of pre-eclampsia and 6 low-birth weights. Insulin administration was needed during the pregnancy in 68% of patients and after childbirth in 31.57% of them. In our control group, all of patients (n = 39) underwent ART (53.8% SET and 46.1% DET) with a 50% (SET) and 61.9% (DET) live birth rate (LBR) per cycle. Patients with RIF/RM, normal BMI, low insulin levels after OGTT could benefit from additional metabolic immune testing. A correct diagnosis and treatment could have a positive impact on their reproductive results and live birth rate.

Indexed as

Reproductive Techniques, AssistedAbortion, HabitualAdultAutoimmunityBirth RateDiabetes MellitusFemaleGlucose Tolerance TestHumansInsulinLive BirthMetforminPancreasPregnancyInsulinMetformin

Identifiers

PMID30346951
PMCPMC6197630

What OpenQuestion holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.